ArticleBirth defects research2026
Investigation of Teratogenic Concerns in the Coronavirus Disease of 2019 Era.
Article in Birth defects research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Investigation of Teratogenic Concerns in the Coronavirus Disease of 2019 Era.Birth defects research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMotherToBaby (MTB) is a teratogen information service that provides information about exposures during pregnancy and breastfeeding to the public and healthcare providers. During the Coronavirus Disease of 2019 (COVID-19) pandemic, MTB received an influx of queries regarding the teratogenicity of the virus and the vaccine. The purpose of this study was to assess the frequency and type of exposures asked about prior to the onset of the COVID-19 pandemic through March 2022 and to evaluate the demographics of individuals who made inquiries.
methodsData from MTB contacts (2018-2022) were accessed through a data-sharing agreement. The data were cleaned and standardized by coding all exposures into 11 established categories before linking demographic and exposure files into a single dataset. Analyses included descriptive statistics, chi-square tests, and logistic regression conducted in Excel and STATA 17.0, with statistical significance set at a 0.01% error rate.
resultsThe total number of contacts increased from 2019 to 2022, and the exposure category with the highest number of contacts was prescription medications, followed by COVID-19-related exposures. Peaks in the number of contacts relating to COVID-19 correlate with various pandemic milestones, such as when vaccines were approved by the U.S. Food and Drug Administration (FDA).
conclusionThese data provide valuable information for healthcare providers and agencies, such as the Centers for Disease Control and Prevention (CDC), to better prepare for future pandemics and epidemics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.